SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (218)9/21/1997 6:50:00 AM
From: David Cathcart   of 1826
 
Rick

I like your comments on Muscoplat. I've always thought that people make the company and it is the first thing I focus on. Muscoplat found Salagen and he found MGI 114. He has a nose for the hidden gems. Blitzer brings new focus to the group and has the leadership skills to take those gems and the company to the next level.

Please further explain your comment about contacting "small companies that specialize in the tissue-and-tumor specific targeting of molecules..." Do you see some potential in combining technologies for a knockout punch to tumors?

I also like a company that lets the results do the taking. In the case of the MGI 114 clinical trials, wouldn't it be nice to know about those results that do the talking a little more often? Waiting for quarterly reports to find out about the status of the trials is a long way between watering holes. This is particularly true now that the dose is at a level that sickens dogs and cures mice. If the past is a guide, the next official information on the clinical trials will be issued about October 15th. The next time after that will be sometime in January of next year.

Incremental changes in the MGI 114 clinical trials - such as dose rates, patient count, signs of efficacy, etc. - do not necessarily warrant a full-scale press release. It would be overkill to issue a press release to say that they just added patient X and the dose level is now at Y. However, that information is of great interest to a small percentage of investors that closely follow the trials. Though the use of SI by a company to spread such valued information may be "tacky," it is not like I'm asking Blitzer to wear a waffle-checked leisure suit. SI would provide a simple way for MGI to release information, with or without comment. This does not imply that MGI should get involved in the dialogue or crazy rhetoric that takes place on SI, and they should not get drawn into responding to any comments posted. Except perhaps this one. :-)

David
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News